Macular Telangiectasia Type 2
Mar 21, 2025
Neurotech’s ENCELTO Makes History as the First and Only FDA-Approved Treatment for MacTel
Neurotech Pharmaceuticals has achieved a significant milestone with the recent FDA approval of its encapsulated cell therapy implant, revakinagene taroretcel, branded as ENCELTO. Approved on March 6, 2025, ENCELTO is the first treatment authorized by the FDA for macular telangiectasia (MacTel) type 2, a rare neurod...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
